Jefferies Financial Group Inc. Buys Shares of 120,000 Zevra Therapeutics, Inc. $ZVRA

Jefferies Financial Group Inc. bought a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 120,000 shares of the company’s stock, valued at approximately $1,075,000. Jefferies Financial Group Inc. owned approximately 0.21% of Zevra Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. raised its stake in Zevra Therapeutics by 15.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after acquiring an additional 550,000 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Zevra Therapeutics by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock worth $29,323,000 after acquiring an additional 130,676 shares during the period. Nantahala Capital Management LLC lifted its stake in shares of Zevra Therapeutics by 34.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock worth $18,753,000 after acquiring an additional 500,000 shares during the period. Rubric Capital Management LP lifted its stake in shares of Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after acquiring an additional 740,584 shares during the period. Finally, Legal & General Group Plc lifted its stake in shares of Zevra Therapeutics by 12.6% in the 3rd quarter. Legal & General Group Plc now owns 1,053,399 shares of the company’s stock worth $10,018,000 after acquiring an additional 117,722 shares during the period. Institutional investors own 35.03% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Guggenheim upped their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, April 11th. Finally, BTIG Research initiated coverage on shares of Zevra Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $23.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.33.

Zevra Therapeutics Stock Up 4.1%

Shares of Zevra Therapeutics stock opened at $11.40 on Friday. The stock’s fifty day moving average is $10.10 and its 200-day moving average is $9.29. The firm has a market capitalization of $673.97 million, a PE ratio of 5.73 and a beta of 0.88. Zevra Therapeutics, Inc. has a 12-month low of $7.16 and a 12-month high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The business had revenue of $36.22 million for the quarter, compared to analyst estimates of $31.96 million. Analysts expect that Zevra Therapeutics, Inc. will post 0.56 EPS for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.